Antiangiogenic Treatment for Multiple CNS Hemangioblastomas

Background: Hemangioblastomas represent rare benign tumors of the central nervous system. In the case of metastatic spread and limited surgical options, systemic treatment may be considered. However there is no standard of care beyond surgery. Case Report: We report the cases of 2 patients with progressive multilocular hemangioblastomas, who showed clinical benefit and radiological stabilization of tumor growth after treatment with bevacizumab, an antibody against the vascular endothelial growth factor. Conclusion: Our case reports suggest activity of bevacizumab in hemangioblastomas after failure of standard therapeutic options.